Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST EBITDA Margin

EBITDA as a percentage of revenue.

Twist Bioscience CorporationNASDAQ: TWST

EBITDA Margin · Q4 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to -33.9%

EBITDA Margin was -33.9% in Q4 FY2026, down 12.8 pp from a year earlier. On a trailing-twelve-month basis it was -28.3%, down 14.5 pp year over year. Over 3 fiscal years it widened by 42.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 8 analysts of -7.1% for the fiscal year ending Sep 2027, up from -28.3% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-33.9%-10.2 pp QoQ
Last fiscal yearSep 2026
-28.3%-14.4 pp YoY
LTMSep 2026
-28.3%-14.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-12.8 pp+9.2 pp+22.0 pp
1 year-14.4 pp+21.1 pp+35.5 pp
3 years+42.8 pp+36.9 pp-5.9 pp
5 years+51.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
-28.3%
Year-over-year change
-14.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's LTM Sep 2026 EBITDA Margin of -28.3% is the lowest of the 2 companies compared; the peer median is 22.3%.
  • Its year-over-year change of -14.5 pp is the lowest of 2, against a peer median of +5.6 pp.
  • Over three fiscal years its change of +42.8 pp compares with a peer median of -9.9 pp.
TWST Competitors Peer median
EBITDA Margin for TWST and competitors
Company Period LTM level YoY 3-year change
RGENRepligen CorporationLTM Jun 202622.3% +5.6 pp-9.9 pp
TWSTTwist Bioscience CorporationLTM Sep 2026-28.3% -14.5 pp+42.8 pp
Peer median (excluding TWST) 22.3%+5.6 pp-9.9 pp

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue203.57M245.11M312.97M376.57M459.43M
Cost of Revenue119.33M155.38M179.63M185.57M218.63M
Gross Profit84.24M89.73M133.35M191M240.8M
Gross Margin41.4%36.6%42.6%50.7%52.4%
Research & Development120.31M106.89M90.85M80.29M71.84M
Selling, General & Admin212.95M189.74M218.4M246.98M301.22M
Operating Expenses319.01M306.89M354.18M327.26M380.26M
Depreciation & Amortization16.51M29.31M31.43M24.85M0
EBITDA(211.68M)(174.15M)(176.71M)(52.1M)(129.8M)
EBITDA Margin-104.0%-71.1%-56.5%-13.8%-28.3%
Operating Income(234.78M)(217.16M)(220.83M)(136.26M)(139.46M)
Operating Margin-115.3%-88.6%-70.6%-36.2%-30.4%
Interest Income3.06M14.37M15.34M11.36M8.8M
Interest Expense80K5K29K00
Other Income / Expenses6.5M13.69M12.67M59.31M8.85M
Income Before Tax(228.27M)(203.47M)(208.17M)(76.95M)(130.61M)
Pre-Tax Margin-112.1%-83.0%-66.5%-20.4%-28.4%
Income Tax Expense(10.41M)1.15M560K719K(406K)
Net Income(217.86M)(204.62M)(208.73M)(77.67M)(130.2M)
Net Margin-107.0%-83.5%-66.7%-20.6%-28.3%
EPS (Basic)(4.04)(3.60)(3.60)(1.30)(2.08)
EPS (Diluted)(4.04)(3.60)(3.60)(1.30)(2.08)
Weighted Avg Shares53.89M56.89M58.02M59.81M62.62M
Weighted Avg Shares (Diluted)53.89M56.89M58.02M59.81M62.62M

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.